首页|The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Amer Soc Hematology
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate. The spectrum of its clinical applications is expanding and is now being tested in other B-cell malignancies. ? 2022 American Society of Hematology
Calabretta E、Hamadani M、Zinzani P.L、Caimi P、Carlo-Stella C
展开 >
Department of Biomedical Sciences, Humanitas University, Milano, Italy
NSTL
Amer Soc Hematology
